PURPOSE: Dabigatran etexilate (DE) constitutes a novel, direct thrombin inhibitor. Regarding the association of thrombin with atherogenesis, we assessed the effects of DE on the development and stability of atherosclerotic lesions in apolipoprotein-E deficient (ApoE-/-) mice. MATERIALS- METHODS: Fifty male ApoE-/- mice were randomized to receive western-type diet either supplemented with DE 7.5 mg DE/g chow) (DE-group, n = 25) or matching placebo as control (CO-group, n = 25) for 12 weeks. After this period, all mice underwent carotid artery injury with ferric chloride and the time to thrombotic total occlusion (TTO) was measured. Then, mice were euthanatized and each aortic arch was analyzed for the mean plaque area, the content of macrophages, elastin, collagen, nuclear factor kappaB (NFκB), vascular cell adhesion molecule-1 (VCAM-1), matrix metalloproteinase-9 (MMP-9) and its inhibitor (TIMP-1). RESULTS: DE-group showed significantly longer TTO compared to CO-group (8.9 ± 2.3 min vs 3.5 ± 1.1 min, p < 0.001) and the mean plaque area was smaller in DE-group than CO-group (441.00 ± 160.01 × 10(3) μm(2) vs 132.12 ± 32.17 × 10(3) μm(2), p < 0.001). Atherosclerotic lesions derived from DE-treated mice showed increased collagen (p = 0.043) and elastin (p = 0.031) content, thicker fibrous caps (p < 0.001) and reduced number of internal elastic lamina ruptures per mm of arterial girth (p < 0.001) when compared to CO-group. Notably, DE treatment seemed to promote plaque stability possibly by reducing concentrations of NFκB, VCAM-1, macrophages and MMP-9 and increasing TIMP-1 within atherosclerotic lesions (p < 0.05). CONCLUSIONS: DE attenuates arterial thrombosis, reduces lesion size and may promote plaque stability in ApoE-/- mice. The plaque-stabilizing effects of chronic thrombin inhibition might be the result of the favorable modification of inflammatory mechanisms.
PURPOSE:Dabigatran etexilate (DE) constitutes a novel, direct thrombin inhibitor. Regarding the association of thrombin with atherogenesis, we assessed the effects of DE on the development and stability of atherosclerotic lesions in apolipoprotein-E deficient (ApoE-/-)mice. MATERIALS- METHODS: Fifty male ApoE-/- mice were randomized to receive western-type diet either supplemented with DE 7.5 mg DE/g chow) (DE-group, n = 25) or matching placebo as control (CO-group, n = 25) for 12 weeks. After this period, all mice underwent carotid artery injury with ferric chloride and the time to thrombotic total occlusion (TTO) was measured. Then, mice were euthanatized and each aortic arch was analyzed for the mean plaque area, the content of macrophages, elastin, collagen, nuclear factor kappaB (NFκB), vascular cell adhesion molecule-1 (VCAM-1), matrix metalloproteinase-9 (MMP-9) and its inhibitor (TIMP-1). RESULTS: DE-group showed significantly longer TTO compared to CO-group (8.9 ± 2.3 min vs 3.5 ± 1.1 min, p < 0.001) and the mean plaque area was smaller in DE-group than CO-group (441.00 ± 160.01 × 10(3) μm(2) vs 132.12 ± 32.17 × 10(3) μm(2), p < 0.001). Atherosclerotic lesions derived from DE-treated mice showed increased collagen (p = 0.043) and elastin (p = 0.031) content, thicker fibrous caps (p < 0.001) and reduced number of internal elastic lamina ruptures per mm of arterial girth (p < 0.001) when compared to CO-group. Notably, DE treatment seemed to promote plaque stability possibly by reducing concentrations of NFκB, VCAM-1, macrophages and MMP-9 and increasing TIMP-1 within atherosclerotic lesions (p < 0.05). CONCLUSIONS: DE attenuates arterial thrombosis, reduces lesion size and may promote plaque stability in ApoE-/- mice. The plaque-stabilizing effects of chronic thrombin inhibition might be the result of the favorable modification of inflammatory mechanisms.
Authors: Marta Cortes-Canteli; Anna Kruyer; Irene Fernandez-Nueda; Ana Marcos-Diaz; Carlos Ceron; Allison T Richards; Odella C Jno-Charles; Ignacio Rodriguez; Sergio Callejas; Erin H Norris; Javier Sanchez-Gonzalez; Jesus Ruiz-Cabello; Borja Ibanez; Sidney Strickland; Valentin Fuster Journal: J Am Coll Cardiol Date: 2019-10-15 Impact factor: 24.094
Authors: Rohun U Palekar; Andrew P Jallouk; Jacob W Myerson; Hua Pan; Samuel A Wickline Journal: Arterioscler Thromb Vasc Biol Date: 2016-01-14 Impact factor: 8.311
Authors: Michael R Preusch; Nicholas Ieronimakis; Errol S Wijelath; Sara Cabbage; Jerry Ricks; Florian Bea; Morayma Reyes; Joanne van Ryn; Michael E Rosenfeld Journal: Drug Des Devel Ther Date: 2015-09-10 Impact factor: 4.162
Authors: Joanne van Ryn; Ashley Goss; Norbert Hauel; Wolfgang Wienen; Henning Priepke; Herbert Nar; Andreas Clemens Journal: Front Pharmacol Date: 2013-02-12 Impact factor: 5.810
Authors: Julian I Borissoff; Jeroen J T Otten; Sylvia Heeneman; Peter Leenders; René van Oerle; Oliver Soehnlein; Sarah T B G Loubele; Karly Hamulyák; Tilman M Hackeng; Mat J A P Daemen; Jay L Degen; Hartmut Weiler; Charles T Esmon; Joanne van Ryn; Erik A L Biessen; Henri M H Spronk; Hugo ten Cate Journal: PLoS One Date: 2013-02-07 Impact factor: 3.240